Early Relapse of Follicular Lymphoma Associated with Poor Outcomes

Share this content:
In follicular lymphoma treated with R-CHOP, progression of disease following diagnosis associated with poor outcomes.
In follicular lymphoma treated with R-CHOP, progression of disease following diagnosis associated with poor outcomes.

In patients with follicular lymphoma who received first-line treatment with R-CHOP, progression of disease within 2 years following diagnosis was associated with poor outcomes, a study published online ahead of print in the Journal of Clinical Oncology has shown.

Because 20% of patients with follicular lymphoma experience disease progression within 2 years of initial treatment with R-CHOP, researchers sought to determine whether early disease progression is associated with poor survival.

For the study, researchers identified 588 patients with stage 2 to 4 follicular lymphoma who received first-line R-CHOP chemoimmunotherapy.

Patients were defined as either experiencing early progression of disease 2 years or less following diagnosis or not experiencing disease progression within 2 years.

Results showed that 19% of the 588 patients experienced early progression of disease, while 71% did not. The other 10% of patients were lost to follow-up or died with progression of disease less than 2 years after diagnosis.

RELATED: Bleomycin, Vincristine Discontinuation Doesn't Affect Efficacy in Hodgkin Lymphoma

Researchers found that 5-year overall survival was 50% in the early progression of disease group versus 90% in the reference group (HR = 6.44; 95% CI: 4.33–9.58).

The findings suggest that progression of disease within 2 years after diagnosis should be further validated as a standard endpoint in clinical trials evaluating patients with untreated follicular lymphoma receiving R-CHOP.

Reference

  1. Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015. [epub ahead of print]. doi: 10.1200/JCO.2014.59.7534.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters